Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Weichai Power Wants Hydrogen to Fuel Us – and Itself
Weichai Power announced that it would insist on developing hydrogen fuel, no matter how the social support for this might wax or wane. The technology is most appropriate for commercial vehicles – a convenient way for the firm to develop.
Oct 03, 2020 05:22 AM